… patients to erlotinib treatment, 40 patients to cabozantinib treatment, and 43 patients to erlotinib
… (erlotinib [n=38], cabozantinib [n=38], erlotinib plus cabozantinib [n=35]). Compared with …

… 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with
advanced squamous cell carcinoma of the lung after first-line platinum-based chemotherapy. …

… In summary, second-line afatinib significantly improved symptoms of … with erlotinib in patients
with SCC of the lung. Mean scores over time also significantly favored afatinib over erlotinib …

… second-line chemotherapies between erlotinib plus bevacizumab and panitumumab, and
erlotinib … The goal of our study was to explore optimal second-line treatment option for patients …

… (OS) with maintenance erlotinib versus second-line erlotinib. Secondary objectives of the …
rate (DCR) between the study arms (erlotinib vs. placebo) during the blinded maintenance …

… The indication of afatinib and erlotinib for SqCC of the lung had not been approved.
However, because the oncologist and patients would still pursue these agents as second-line …

… erlotinib therapy may be most beneficial in patients with good response to first-line erlotinib,
… In brief, it is conceivable that patients with slow PD could benefit from continuation of EGFR …

… Our study retrospectively enrolled patients who had received gefitinib, erlotinib or afatinib
for first-line treatment of stage IV or post-operative recurrent (advanced) NSCLC between 2014/…

… phase II trial of second- or third-line erlotinib treatment in elderly patients with NSCLC. The
primary endpoint was overall response rate (ORR) and the secondary endpoints were PFS, …

… erlotinib metabolism versus non-smoking patients, which reduces exposure. Therefore, an
increased erlotinib … and safety of 300 mg erlotinib (E300) as second-line therapy in current …